Rimeporide

Rimeporide

File:Rimeporide skeletal.svg
Systematic (IUPAC) name
N-(2-methyl-4,5-bis(methylsulfonyl)benzoyl)guanidine
Clinical data
Legal status	Experimental
Identifiers
CAS Number	187870-78-6
ATC code	none
PubChem	CID: 9799487
ChemSpider	7975252
UNII	QH6B4V5743
ChEMBL	CHEMBL2107802
Chemical data
Formula	C11H15N3O5S2
Molecular mass	333.38 g·mol−1
SMILES Cc1cc(c(cc1C(=O)NC(=N)N)S(=O)(=O)C)S(=O)(=O)C
InChI InChI=1S/C11H15N3O5S2/c1-6-4-8(20(2,16)17)9(21(3,18)19)5-7(6)10(15)14-11(12)13/h4-5H,1-3H3,(H4,12,13,14,15) Key:GROMEQPXDKRRIE-UHFFFAOYSA-N

Rimeporide is an experimental drug for the treatment of Duchenne muscular dystrophy, being developed by the EspeRare foundation. it has been granted orphan drug status by the European Medicines Agency.

Mechanism of action

The substance blocks an ion pump called sodium–hydrogen antiporter 1 (NHE-1). While the exact mechanism is unknown, it is speculated that inhibition of this pump reduces sodium and calcium overload in cells of Duchenne patients.

History

Rimeporide was designed as a treatment for chronic heart failure. It was unsuccessful in Phase I clinical trials, but was tolerated well by volunteers. Subsequently, the drug was sold to EspeRare, a Swiss nonprofit organisation that aims at developing drugs for rare diseases. As of May 2015, the substance is in preclinical development for Duchenne.

See also

Other drugs for Duchenne muscular dystrophy

• Ataluren
• Biostrophin (experimental)
• Idebenone (experimental)